Therapeutic interventions are being developed for Huntington’s
disease (HD), a hallmark of which is mutant huntingtin protein (mHTT)
aggregates. Following the advancement to human testing of two [11C]-PET ligands for aggregated mHTT, attributes for further
optimization were identified. We replaced the pyridazinone ring of
CHDI-180 with a pyrimidine ring and minimized off-target binding using
brain homogenate derived from Alzheimer’s disease patients.
The major in vivo metabolic pathway via aldehyde
oxidase was blocked with a 2-methyl group on the pyrimidine ring.
A strategically placed ring-nitrogen on the benzoxazole core ensured
high free fraction in the brain without introducing efflux. Replacing
a methoxy pendant with a fluoro-ethoxy group and introducing deuterium
atoms suppressed oxidative defluorination and accumulation of [18F]-signal in bones. The resulting PET ligand, CHDI-650, shows
a rapid brain uptake and washout profile in non-human primates and
is now being advanced to human testing.